Latest news

• MHRA grants two new marketing authorisations for UCB's inflammatory disease drug

  Bimzelx is now approved to treat psoriatic arthritis and axial spondyloarthritis. ... PsA) and axial spondyloarthritis (axSpA).

• AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

  Rinvoq is already approved to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis and atopic dermatitis.

• European Commission grants two new marketing authorisations for UCB's Bimzelx

  The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis. ... The European Commission (EC) has granted UCB's Bimzelx (bimekizumab) two new approvals, with the inflammatory disease drug now authorised to treat certain adults with

• AbbVie’s Rinvoq approved by EC for Crohn's disease

  The therapy is also already approved in the EU for adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, as well as for adults

• Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

  Safety in this paediatric population was consistent with the known safety profile of Cosentyx for the treatment of adult and paediatric plaque psoriasis, PsA and axial spondyloarthritis, the company reported.